Abstract:Huntington's disease (HD) is a neurodegenerative disorder caused by an expanded CAG repeat mutation in the Huntingtin ( HTT ) gene. The mutation impacts neuronal protein homeostasis and cortical/striatal circuitry. SUMOylation is a post-translational modification with broad cellular effects including via modification of synaptic proteins. Here, we used an optimised SUMO protein-enrichment and mass spectrometry method to identify the protein SUMOylation/SUMO interaction proteome in the context of HD using R6/2 transgenic and non-transgenic (NT) mice. Significant changes in enrichment of SUMOylated and SUMO-interacting proteins were observed, including those involved in presynaptic function, cytomatrix at the active zone scaffolding, cytoskeleton organization, and glutamatergic signaling. Mitochondrial and RNA-binding proteins also showed altered enrichment. Modified SUMO-associated pathways in HD tissue include clathrin-mediated endocytosis signaling, synaptogenesis signaling, synaptic long-term potentiation, and SNARE signaling. To evaluate how modulation of SUMOylation might influence functional measures of neuronal activity in HD cells in vitro , we utilised primary neuronal cultures from R6/2 and NT mice. A receptor internalization assay for the metabotropic glutamate receptor 7 (mGLUR7), a SUMO enriched protein in the mass spec, showed decreased internalization in R6/2 neurons compared to NT. siRNA-mediated knockdown of the E3 SUMO ligase Protein Inhibitor of Activated STAT1 ( Pias1 ), which can SUMO modify mGLUR7, prevented this HD phenotype. In addition, microelectrode array analysis of primary neuronal cultures indicated early hyperactivity in HD cells, while later timepoints demonstrated deficits in several measurements of neuronal activity within cortical neurons. HD phenotypes were rescued at selected timepoints following knockdown of Pias1 . Collectively, our results provide a mouse brain SUMOome resource and show that significant alterations occur within the post-translational landscape of SUMO-protein interactions of synaptic proteins in HD mice, suggesting that targeting of synaptic SUMO networks may provide a proteostatic systems-based therapeutic approach for HD and other neurological. Disorders.

Epigenetic Dysregulation of Hairy and Enhancer of Split 4 (hes4) is Associated with Striatal Degeneration in Postmortem Huntington Brains

DNA methylation study of Huntington’s disease and motor progression in patients and in animal models

Genome-wide Loss of 5-Hmc is a Novel Epigenetic Feature of Huntington's Disease.

Dysregulation of protein SUMOylation networks in Huntington's disease R6/2 mouse striatum

Huntingtin loss-of-function contributes to transcriptional deregulation in Huntington's disease

Msh3 and Pms1 Set Neuronal CAG-repeat Migration Rate to Drive Selective Striatal and Cortical Pathogenesis in HD Mice

Poly ADP-Ribose Signaling is Dysregulated in Huntington Disease Patients

Multi-epitope immunocapture of huntingtin reveals striatum-selective molecular signatures

Chromatin remodeler BRG1 recruits huntingtin to repair DNA double-strand breaks in neurons

Loss of Hap1 Selectively Promotes Striatal Degeneration in Huntington Disease Mice

Ubiquitin-Activating Enzyme Activity Contributes to Differential Accumulation of Mutant Huntingtin in Brain and Peripheral Tissues

Context-dependent Dysregulation of Transcription by Mutant Huntingtin

Long somatic DNA-repeat expansion drives neurodegeneration in Huntington disease

PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington's disease

HAP40 Modulates Mutant Huntingtin Aggregation and Toxicity in Huntington’s Disease Mice

A Huntingtin-Associated Protein Enriched in Brain with Implications for Pathology

Interaction of Huntington disease protein with transcriptional activator Sp1.

HAP40 modulates mutant Huntingtin aggregation and toxicity in Huntington's disease mice

PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD)

Aberrant splicing in Huntington's disease via disrupted TDP-43 activity accompanied by altered m6A RNA modification

Impaired Α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Trafficking and Function by Mutant Huntingtin